Table 4.
Clinical trials of immune checkpoint inhibitors after autologous hematopoietic stem cell transplantation (HSCT).
| Trial ID (Name) | Authors | Year | Intervention(s) | Phase | Disease(s) | N | CR | OR | PFS |
|---|---|---|---|---|---|---|---|---|---|
|
NCT00060372 (CTEP 6082) |
Bashey et al. | 2009 | Ipilimumab after allo-HSCT | I | cHL B-NHL |
14 3 |
14% 0% |
14% 33% |
N.A. |
| NCT00532259 | Armand et al. | 2013 | Pidilizumab after auto-HSCT | II | DLBCL | 35 | 34% | 51% | 72% at 16 months |
| NCT01822509 | Davids et al. | 2016 | Ipilimumab after allo-HSCT | I/Ib | cHL B-NHL |
7 4 |
0% 0% |
14% 0% |
N.A. |
| NCT01919619 | Khouri et al. | 2018 | Ipilimumab + Lenalidomide after HSCT | II | B-NHL (allo-HSCT) B-NHL (auto-HSCT) |
8 6 |
38% 83% |
75% 83% |
56% at 12 months 86% at 12 months |
| NCT02362997 | Frigault et al. | 2020 | Pembrolizumab after auto-HSCT | II | DLBCL | 29 | 59% | 59% | 58% at 18.5 months |
All disease groups are relapsed/refractory unless otherwise specified. Abbreviations: N, number of patients; CR, complete response, OR, overall response; PFS, progression free survival; N.A., not assessed.